Endpoints News
421 articles in the TruthFoundry index. Each links out to the original.
- Ultragenyx announces 20% layoffs, cancels Wilson disease gene therapy · Biotech firm Ultragenyx will cut 20% of staff and end a Wilson disease gene therapy program.
- Servier $1.55B muscular dystrophy drug sevasemten fails pivotal trial · Servier's acquired muscular dystrophy drug sevasemten failed its pivotal clinical trial.
- US midterm election outcomes will impact biopharma industry policy · Endpoints News will host live analysis of US midterm effects on biopharma.
- Health tech article content locked behind publisher paywall · Full health tech discussion content is restricted behind user sign up requirements
- Pfizer raises 2026 guidance offsetting Covid product sales decline · Pfizer lifted 2026 guidance as cancer and migraine sales offset falling Covid revenue
- Bayer CEO confirms company is working on US MFN agreement · Bayer CEO Bill Anderson stated the firm is working on a US most favored nation agreement.
- AbbVie signs deal with Brise Pharma for preclinical migraine medications · AbbVie agreed to a discovery and commercialization deal with Brise Pharma for two preclinical migraine programs.
- uniQure gets FDA review date; Inovia stock surges after approval · FDA sets review timeline for uniQure, Inovia stock rises on regulatory approval
- FDA places Bright Minds Biosciences seizure drug on partial clinical hold · Bright Minds Biosciences announced the FDA placed its experimental seizure drug on partial hold.
- CinRx partners with Sam Waksal's Graviton on ROCK2 cardiac therapies · CinRx and Graviton Bioscience announce partnership for ROCK2 cardiovascular drug development
- Endpoints Weekly Halloween edition locked behind sign up wall · Full Endpoints Weekly article content requires user sign up, login or premium subscription.
- Sanofi may raise European drug prices instead of withholding launches under Trump policy · Pharmaceutical firm Sanofi may increase European drug prices under Trump administration pricing policies
- Gilead places CAR-T therapy on partial clinical hold · Gilead paused CAR-T trials, while Agios had its PDUFA review date delayed.
- Sanofi rules out major overhaul ahead of Dupixent patent expiration · Sanofi confirmed no major corporate overhaul is planned as Dupixent patent expiry nears
- Former Be Bio CEO Joanne Smith-Farrell joins Orbis Medicines after shutdown · Ex-Be Bio CEO Joanne Smith-Farrell has joined Lilly and Novo backed Orbis Medicines.
- Post-Hoc Live to discuss AI-run zero-employee biotech startups · Endpoints News will host a live discussion on tiny AI-powered biotech startups.
- UK secures £500M biopharma pledges; Teva closing New Jersey site · UK receives £500M biopharma investment pledges while Teva will close its New Jersey facility.
- Ono Pharma drug fails five trials; Lenz and Molecular Partners plan layoffs · Ono Pharma's ONO-1110 failed five trials, with layoffs announced at two biotech firms.
- Personal AI agents are being developed for healthcare industry use · Technology firms and startups are building personal AI agents for healthcare applications.
- Anthropic outlines biopharma vision day after filing for major IPO · Anthropic revealed its biopharma research plans one day after filing for a large IPO.
- Major US firms block personal AI agents while Zocdoc enables them · Amazon, Delta, and major US banks have blocked personal AI agent usage on their services.
- FDA outlines approval pathway for individualized gene editing therapies · US FDA published guidance for approval of custom single-patient gene editing medicines
- HHS ends enforcement of ban on compounding select wellness peptides · US HHS announced it will stop enforcing a ban on compounding certain wellness peptides.
- Analysts Scrutinize Biogen Lupus Drug Ahead Of Critical Phase 3 Results · Analysts are questioning Biogen's litifilimab ahead of pivotal Phase 3 trial readouts.
- Pfizer India cancer drug factory closed for up to two years · Pfizer temporarily closed an India cancer drug factory, risking supply shortages.
- Beijing biotech BioGeometry secures over $100M Series A for AI drug R&D · Chinese biotech startup BioGeometry raised over $100M Series A for AI protein design.
- Eli Lilly retatrutide outperforms Novo Ozempic for diabetes treatment · Eli Lilly's retatrutide demonstrates superior diabetes performance versus Novo Nordisk's Ozempic.
- Astellas secures exclusive license option for Audax preclinical cancer drug · Astellas obtained an exclusive option to license Audax Biosciences' preclinical IL-12 cancer drug.
- Amish and Mennonite communities back new gene therapy company formation · Amish and Mennonite groups support the launch of a new gene therapy firm in Pennsylvania.
- US Judge Allows Eli Lilly Ads After Rejecting Novo Nordisk Challenge · A US judge rejected Novo Nordisk's challenge, permitting Eli Lilly advertisements to continue.